For a considerable duration, scientific observation has pointed to a curious correlation: individuals residing at elevated altitudes, characterized by attenuated atmospheric oxygen concentrations, exhibit a demonstrably lower incidence of diabetes mellitus compared to their counterparts inhabiting sea-level regions. While this epidemiological trend has been robustly documented, the underlying biological mechanisms responsible for this protective effect remained largely enigmatic, eluding definitive scientific explanation. A recent breakthrough by researchers at the Gladstone Institutes has now illuminated this persistent physiological puzzle, identifying a pivotal role for red blood cells in this phenomenon. Their extensive investigation reveals that under conditions of reduced oxygen availability, erythrocytes undergo a profound metabolic transformation, leading them to absorb substantial quantities of glucose from the circulatory system. Essentially, these cells, in an environment mimicking the rarefied air found atop the world’s highest peaks, function as highly efficient "sugar sponges."
The findings, meticulously detailed in the esteemed scientific journal Cell Metabolism, present compelling evidence that erythrocytes possess the remarkable capacity to recalibrate their metabolic pathways in response to diminished oxygen tension. This adaptive shift not only enhances their efficiency in delivering oxygen to vital tissues at high altitudes but, critically, results in a significant reduction of circulating blood glucose levels, thereby offering a plausible explanation for the observed lower prevalence of diabetes. Dr. Isha Jain, a senior author of the study and a distinguished Investigator at Gladstone, a core investigator at the Arc Institute, and a professor of biochemistry at the University of California, San Francisco, emphasized the study’s significance in resolving a protracted question within the field of human physiology. She articulated that red blood cells represent an hitherto unappreciated "hidden compartment" of glucose metabolism, suggesting that this revelation could catalyze entirely novel therapeutic strategies for managing blood sugar regulation.
The Jain laboratory has dedicated years to the comprehensive study of hypoxia, the medical term denoting a deficiency of oxygen in the body’s tissues, and its multifaceted impacts on metabolic processes. During their prior experimental endeavors, the research team observed a striking phenomenon in mice subjected to low-oxygen atmospheres: a dramatic and sustained decrease in blood glucose concentrations. These animals demonstrated an accelerated clearance of sugar from their bloodstream following nutrient ingestion, a characteristic typically associated with a reduced risk of developing diabetes. However, when investigators meticulously examined the major organs to pinpoint the precise location of this glucose utilization, no definitive answer emerged. Dr. Yolanda Martín-Mateos, a postdoctoral scholar in Jain’s lab and the lead author of the groundbreaking study, recounted the perplexing observation that ingested sugar would vanish from the bloodstream almost instantaneously in hypoxic mice. She noted that extensive investigation of all the usual suspects – including muscle, brain, and liver tissues – failed to account for the observed rapid glucose depletion.
Employing a novel imaging methodology, the research team made a pivotal discovery: red blood cells were actively functioning as the missing "glucose sink," meaning they were actively sequestering and metabolizing substantial amounts of glucose from the bloodstream. This finding was particularly unexpected, given the long-held scientific consensus that traditionally characterizes erythrocytes primarily as passive carriers of oxygen. Subsequent experiments conducted with mice provided robust confirmation of this initial observation. Under conditions of induced hypoxia, the animal subjects not only exhibited an overall increase in red blood cell production but also demonstrated a markedly heightened capacity for individual red blood cells to absorb glucose when compared to erythrocytes developed under normoxic, or normal oxygen, conditions.
To elucidate the intricate molecular mechanisms underpinning this metabolic recalibration, Dr. Jain’s group forged a collaborative partnership with Dr. Angelo D’Alessandro from the University of Colorado Anschutz Medical Campus and Dr. Allan Doctor from the University of Maryland, both of whom possess extensive expertise in the biology of red blood cells. Their joint research efforts revealed that in environments with limited oxygen, erythrocytes utilize glucose to synthesize a specific molecule that facilitates the release of oxygen to the body’s tissues. This particular metabolic pathway becomes critically important when the supply of oxygen is severely constrained. Dr. D’Alessandro expressed his profound surprise at the sheer magnitude of this effect, highlighting that while red blood cells are typically regarded as inert oxygen transporters, the study uncovered their ability to account for a significant portion of whole-body glucose consumption, particularly under hypoxic conditions.
Beyond the immediate physiological implications, the researchers also uncovered that the metabolic advantages conferred by prolonged hypoxic exposure persisted for an extended period, lasting for weeks to months even after the mice were returned to ambient oxygen levels. Building upon these findings, the team proceeded to evaluate HypoxyStat, a novel therapeutic agent developed in Dr. Jain’s laboratory that effectively mimics the physiological effects of low-oxygen exposure. Administered orally, HypoxyStat functions by augmenting the affinity of hemoglobin within red blood cells for oxygen, thereby moderating the amount of oxygen released to peripheral tissues. In preclinical models of diabetes in mice, this innovative medication demonstrated a remarkable ability to completely reverse hyperglycemia (high blood sugar) and significantly outperformed existing therapeutic interventions.
Dr. Jain underscored the significance of this research, noting that it represents one of the initial applications of HypoxyStat beyond its intended use in mitochondrial diseases. She suggested that this discovery heralds a paradigm shift in the conceptualization of diabetes treatment, proposing the novel approach of leveraging red blood cells as active glucose-lowering agents. The potential ramifications of these findings may extend beyond the realm of diabetes management. Dr. D’Alessandro pointed out the potential relevance of this research to the field of exercise physiology, as well as to the management of pathological hypoxia that can occur following traumatic injuries. Trauma remains a leading cause of mortality among younger populations, and alterations in red blood cell production and metabolic activity could profoundly influence glucose availability and muscular performance in such cases. Dr. Jain concluded by emphasizing that this research marks merely the inception of a larger scientific endeavor, with a vast landscape of knowledge yet to be explored regarding the intricate ways in which the human body adapts to fluctuating oxygen levels and how these adaptive mechanisms might be harnessed for the treatment of a wide spectrum of medical conditions.
The comprehensive study, bearing the title "Red Blood Cells Serve as a Primary Glucose Sink to Improve Glucose Tolerance at Altitude," was officially published in Cell Metabolism on February 19, 2026. The collaborative research effort involved a multidisciplinary team of scientists, including Yolanda Martín-Mateos, Ayush D. Midha, Will R. Flanigan, Tej Joshi, Helen Huynh, Brandon R. Desousa, Skyler Y. Blume, and Isha Jain from Gladstone; Zohreh Safari, Stephen Rogers, and Allan Doctor from the University of Maryland; and Shaun Bevers, Aaron V. Issaian, and Angelo D’Alessandro from the University of Colorado Anschutz. The research was generously supported by grants from the National Institutes of Health (under grant numbers DP5 OD026398, R01 HL161071, R01 HL173540, R01 HL146442, R01 HL149714, and DP5 OD026398), the California Institute for Regenerative Medicine, and foundational support from Dave Wentz, the Hillblom Foundation, and the W.M. Keck Foundation.
About the Author
